Health
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in USImproves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolioBuilds on established experience and leadership in oncology and immunology biosimilars Basel, June 2, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25)
About this update from Sandoz Group Ltd
[{"type":"image","alt":"Sandoz Group","displaySize":"","headline":null,"caption":"Sandoz Group","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":41,"url":"https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qaCYsKqoASJVSMd1vUCp9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25","width":300,"height":41}},"lazy":false},{"type":"text","content":"Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules","length":72,"tagName":"p"},{"type":"text","content":"MEDIA RELEASE","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Builds on established experience and leadership in oncology and immunology biosimilars","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":357,"olType":false},{"type":"text","content":"Basel, June 2, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, has announced that WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are available to patients in the US starting today. WYOST® and Jubbonti® are the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of the reference medicines XGEVA®* (denosumab) and Prolia®* (denosumab), respectively.[2,3]","length":461,"tagName":"p"},{"type":"text","content":"This launch builds on Sandoz established leadership in biosimilars and oncology, dating back to the introduction of the first biosimilar in the US in 2015. WYOST® and Jubbonti® are key biosimilar value drivers that are integral to the Sandoz growth strategy, representing a significant step forward in advancing the Company’s ambition to be the biosimilar leader in the US.","length":373,"tagName":"p"},{"type":"text","content":"Keren Haruvi, President Sandoz North America, said: “Denosumab is a vita...